CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Tacrolimus

他克莫司 杂质对照品Tacrolimus Impurities

EPUSP39 个杂质条目39 impurity entries

本页汇总 他克莫司 的 39 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 39 impurity reference standards of Tacrolimus with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 他克莫司(Tacrolimus)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesValidation of Analytical Methods for Tacrolimus Determination in Poly(ε-caprolactone) Nanocapsules and Identification of Drug Degradation Products
    Journal of nanoscience and nanotechnology · 2021 · Camargo GA et al.  ·  PMID 34229787  ·  DOI
  2. 杂质研究Impurity studiesAn improved validated ultra high pressure liquid chromatography method for separation of tacrolimus impurities and its tautomers
    Drug testing and analysis · 2010 · Subasranjan A et al.  ·  PMID 20878891  ·  DOI
  3. 杂质研究Impurity studiesForced degradation of tacrolimus and the development of a UHPLC method for impurities determination
    Acta pharmaceutica (Zagreb, Croatia) · 2019 · Peterka TR et al.  ·  PMID 31259735  ·  DOI
  4. 分析方法Analytical MethodsDevelopment and validation of a rapid HPLC-MS/MS method for simultaneous determination of cyclosporine A and tacrolimus in whole blood for routine therapeutic drug monitoring in organ transplantation
    Rapid communications in mass spectrometry : RCM · 2025 · Han FF et al.  ·  PMID 39530138  ·  DOI
  5. 分析方法Analytical MethodsSimultaneous quantification of cyclosporin, tacrolimus, sirolimus and everolimus in whole blood by UHPLC-MS/MS for therapeutic drug monitoring
    Biomedical chromatography : BMC · 2021 · Antunes NJ et al.  ·  PMID 33462848  ·  DOI

他克莫司 —— 原料药与杂质对照品Tacrolimus — drug substance & impurities

共 40 个条目(含原料药本体)40 items incl. the drug substance
Tacrolimus structure
EP原料药 APIAPI
他克莫司Tacrolimus
Tacrolimus
CAS No.104987-11-3
Chemical FormulaC44H69NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 1 (Tacrolimus Monohydrate EP Impurity D) (Tacrolimus 8-Epimer) structure
EPD
他克莫司杂质1 (他克莫司一水合物EP杂质D) (他克莫司8-差向异构体)Tacrolimus Impurity 1 (Tacrolimus Monohydrate EP Impurity D) (Tacrolimus 8-Epimer)
Tacrolimus Impurity 1 (Tacrolimus Monohydrate EP Impurity D) (Tacrolimus 8-Epimer)
CAS No.129212-35-7
Chemical FormulaC44H69NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 6 (Tacrolimus Monohydrate EP Impurity E) (Tacrolimus 8-Propyl Analog) structure
EPE
他克莫司杂质6 (他克莫司一水合物EP杂质E) (他克莫司8-丙基类似物)Tacrolimus Impurity 6 (Tacrolimus Monohydrate EP Impurity E) (Tacrolimus 8-Propyl Analog)
Tacrolimus Impurity 6 (Tacrolimus Monohydrate EP Impurity E) (Tacrolimus 8-Propyl Analog)
CAS No.104987-30-6
Chemical FormulaC44H71NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 14 (Tacrolimus Monohydrate EP Impurity F) structure
EPF
他克莫司杂质14 (他克莫司一水合物EP杂质F)Tacrolimus Impurity 14 (Tacrolimus Monohydrate EP Impurity F)
Tacrolimus Impurity 14 (Tacrolimus Monohydrate EP Impurity F)
CAS No.1393890-33-9
Chemical FormulaC44H69NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 8 (Tacrolimus Monohydrate EP Impurity G) (Tacrolimus 19-Epimer) structure
EPG
他克莫司杂质8 (他克莫司一水合物EP杂质G) (他克莫司19-差向异构体)Tacrolimus Impurity 8 (Tacrolimus Monohydrate EP Impurity G) (Tacrolimus 19-Epimer)
Tacrolimus Impurity 8 (Tacrolimus Monohydrate EP Impurity G) (Tacrolimus 19-Epimer)
CAS No.144490-63-1
Chemical FormulaC44H69NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 12 (Tacrolimus Monohydrate EP Impurity H) structure
EPH
他克莫司杂质12 (他克莫司一水合物EP杂质H)Tacrolimus Impurity 12 (Tacrolimus Monohydrate EP Impurity H)
Tacrolimus Impurity 12 (Tacrolimus Monohydrate EP Impurity H)
CAS No.143210-33-7
Chemical FormulaC43H69NO11
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 4 (Tacrolimus Monohydrate EP Impurity I) (Tacrolimus Diene) structure
EPI
他克莫司杂质4 (他克莫司一水合物EP杂质I) (他克莫司二烯)Tacrolimus Impurity 4 (Tacrolimus Monohydrate EP Impurity I) (Tacrolimus Diene)
Tacrolimus Impurity 4 (Tacrolimus Monohydrate EP Impurity I) (Tacrolimus Diene)
CAS No.104987-16-8
Chemical FormulaC44H67NO11
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 38 (Tacrolimus USP Related Compound A ) structure
USPA
他克莫司杂质38 (他克莫司 USP 相关化合物A)Tacrolimus Impurity 38 (Tacrolimus USP Related Compound A )
Tacrolimus Impurity 38 (Tacrolimus USP Related Compound A )
CAS No.135635-46-0
Chemical FormulaC43H69NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 2(Tacrolimus Methyl Acryl Aldehyde) structure
2
他克莫司杂质2( 他克莫司甲基丙烯醛)Tacrolimus Impurity 2(Tacrolimus Methyl Acryl Aldehyde)
Tacrolimus Impurity 2(Tacrolimus Methyl Acryl Aldehyde)
CAS No.109466-74-2
Chemical FormulaC11H18O3
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 4 structure
4
他克莫司杂质4Tacrolimus Impurity 4
Tacrolimus Impurity 4
CAS No.129212-37-9
Chemical FormulaC44H67NO11
Purity>95%现货In stock
10mg25mg50mg100mg
Tacrolimus Impurity 9 (Tacrolimus Open Ring (USP)) structure
9
他克莫司杂质9(他克莫司开环(USP))Tacrolimus Impurity 9 (Tacrolimus Open Ring (USP))
Tacrolimus Impurity 9 (Tacrolimus Open Ring (USP))
CAS No.144432-23-5
Chemical FormulaC44H71NO13
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 13 (Positional Isomer ) structure
13
他克莫司杂质13(位置异构体)Tacrolimus Impurity 13 (Positional Isomer )
Tacrolimus Impurity 13 (Positional Isomer )
CAS No.131944-48-4
Chemical FormulaC44H69NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 15 (31-Desmethyltacrolimus) (M-II) structure
15
他克莫司杂质15 (31-去甲基他克莫司) (M-II)Tacrolimus Impurity 15 (31-Desmethyltacrolimus) (M-II)
Tacrolimus Impurity 15 (31-Desmethyltacrolimus) (M-II)
CAS No.127984-76-3
Chemical FormulaC43H67NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 18 structure
18
他克莫司杂质18Tacrolimus Impurity 18
Tacrolimus Impurity 18
CAS No.123719-19-7
Chemical FormulaC43H69NO11
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 22(Tacrolimus Hydroxy Acid Impurity) structure
22
他克莫司杂质22(他克莫司羟基酸杂质)Tacrolimus Impurity 22(Tacrolimus Hydroxy Acid Impurity)
Tacrolimus Impurity 22(Tacrolimus Hydroxy Acid Impurity)
CAS No.1700657-83-5
Chemical FormulaC44H71NO13
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 23 (13-O-Desmethyl Tacrolimus) (M-I) structure
23
他克莫司杂质23 (13-O-去甲基他克莫司) (M-I)Tacrolimus Impurity 23 (13-O-Desmethyl Tacrolimus) (M-I)
Tacrolimus Impurity 23 (13-O-Desmethyl Tacrolimus) (M-I)
CAS No.132172-14-6
Chemical FormulaC43H67NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 24 (Tacrolimus Lactone Isomer) (Iso-FK 506) structure
24
他克莫司杂质24 (他克莫司内酯异构体) (Iso-FK 506)Tacrolimus Impurity 24 (Tacrolimus Lactone Isomer) (Iso-FK 506)
Tacrolimus Impurity 24 (Tacrolimus Lactone Isomer) (Iso-FK 506)
CAS No.134590-88-8
Chemical FormulaC44H69NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 31 structure
31
他克莫司杂质31Tacrolimus Impurity 31
Tacrolimus Impurity 31
CAS No.135821-70-4
Chemical FormulaC44H67NO11
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 40 structure
40
他克莫司杂质40Tacrolimus Impurity 40
Tacrolimus Impurity 40
CAS No.135635-47-1
Chemical FormulaC43H67NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 48 structure
48
他克莫司杂质48Tacrolimus Impurity 48
Tacrolimus Impurity 48
CAS No.129039-81-2
Chemical FormulaC43H65NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 50 structure
50
他克莫司杂质50Tacrolimus Impurity 50
Tacrolimus Impurity 50
CAS No.1190108-68-9
Chemical FormulaC45H70N2O13
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 51 structure
51
他克莫司杂质51Tacrolimus Impurity 51
Tacrolimus Impurity 51
CAS No.1190108-75-8
Chemical FormulaC46H70N2O13
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 52 structure
52
他克莫司杂质52Tacrolimus Impurity 52
Tacrolimus Impurity 52
CAS No.1801371-09-4
Chemical FormulaC48H75NO14
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 53 structure
53
他克莫司杂质53Tacrolimus Impurity 53
Tacrolimus Impurity 53
CAS No.138118-01-1
Chemical FormulaC52H87NO12SSi
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 57 (15-Desmethyltacrolimus) (M-III) structure
57
他克莫司杂质57 (15-去甲基他克莫司) (M-III)Tacrolimus Impurity 57 (15-Desmethyltacrolimus) (M-III)
Tacrolimus Impurity 57 (15-Desmethyltacrolimus) (M-III)
CAS No.151039-41-7
Chemical FormulaC43H67NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 68 structure
68
他克莫司杂质68Tacrolimus Impurity 68
Tacrolimus Impurity 68
CAS No.143289-48-9
Chemical FormulaC43H69NO11
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 71 structure
71
他克莫司杂质71Tacrolimus Impurity 71
Tacrolimus Impurity 71
CAS No.157141-17-8
Chemical FormulaC42H65NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 79 structure
79
他克莫司杂质79Tacrolimus Impurity 79
Tacrolimus Impurity 79
CAS No.1026775-21-2
Chemical FormulaC44H69NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 83 structure
83
他克莫司杂质83Tacrolimus Impurity 83
Tacrolimus Impurity 83
CAS No.135821-69-1
Chemical FormulaC44H71NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 87 (13-O-Desmethyl Tacrolimus) structure
87
他克莫司杂质87 (13-O-去甲基他克莫司)Tacrolimus Impurity 87 (13-O-Desmethyl Tacrolimus)
Tacrolimus Impurity 87 (13-O-Desmethyl Tacrolimus)
CAS No.139958-51-3
Chemical FormulaC43H67NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 92 structure
92
他克莫司杂质92Tacrolimus Impurity 92
Tacrolimus Impurity 92
CAS No.1262804-11-4
Chemical FormulaC45H71NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 100 structure
100
他克莫司杂质100Tacrolimus Impurity 100
Tacrolimus Impurity 100
CAS No.161861-18-3
Chemical FormulaC44H67NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 103 structure
103
他克莫司杂质103Tacrolimus Impurity 103
Tacrolimus Impurity 103
CAS No.1260758-24-4
Chemical FormulaC10H15NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 104 structure
104
他克莫司杂质104Tacrolimus Impurity 104
Tacrolimus Impurity 104
CAS No.161861-10-5
Chemical FormulaC45H71NO13
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 105 structure
105
他克莫司杂质105Tacrolimus Impurity 105
Tacrolimus Impurity 105
CAS No.686773-61-5
Chemical FormulaC44H69NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 106 structure
106
他克莫司杂质106Tacrolimus Impurity 106
Tacrolimus Impurity 106
CAS No.1242656-50-3
Chemical FormulaC44H69NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 107 structure
107
他克莫司杂质107Tacrolimus Impurity 107
Tacrolimus Impurity 107
CAS No.1489143-84-1
Chemical FormulaC44H69NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 111 structure
111
他克莫司杂质111Tacrolimus Impurity 111
Tacrolimus Impurity 111
CAS No.375793-88-7
Chemical FormulaC44H71NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 112 structure
112
他克莫司杂质112Tacrolimus Impurity 112
Tacrolimus Impurity 112
CAS No.211761-99-8
Chemical FormulaC44H71NO12
Purity>95%询价On request
10mg25mg50mg100mg
Tacrolimus Impurity 113 (13-O-Desmethylascomycin) structure
113
他克莫司杂质113 (13-O-去甲基子囊霉素)Tacrolimus Impurity 113 (13-O-Desmethylascomycin)
Tacrolimus Impurity 113 (13-O-Desmethylascomycin)
CAS No.153781-48-7
Chemical FormulaC42H67NO12
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

他克莫司 —— 研究文献与合成路线Tacrolimus — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 他克莫司 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Tacrolimus. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Forced degradation of tacrolimus and the development of a UHPLC method for impurities determination
    Peterka TR, Lušin TT, Bergles J, et al. · Acta pharmaceutica (Zagreb, Croatia) · 2019 · 被引 7cited 7
  2. Stability characterization, kinetics and mechanism of tacrolimus degradation in cyclodextrin solutions
    Prajapati M, Eiriksson FF, Loftsson T · International journal of pharmaceutics · 2020 · 被引 11cited 11
  3. Predicting drug release and degradation kinetics of long-acting microsphere formulations of tacrolimus for subcutaneous injection
    Gao GF, Ashtikar M, Kojima R, et al. · Journal of controlled release : official journal of the Controlled Release Society · 2021 · 被引 27cited 27
  4. Evaluation, synthesis and characterization of tacrolimus impurities
    Ferraboschi P, Colombo D, De Mieri M, et al. · The Journal of antibiotics · 2012 · 被引 9cited 9
  5. Solid state compatibility study and characterization of a novel degradation product of tacrolimus in formulation
    Rozman Peterka T, Grahek R, Hren J, et al. · Journal of pharmaceutical and biomedical analysis · 2015 · 被引 7cited 7
  6. Validation of Analytical Methods for Tacrolimus Determination in Poly(ε-caprolactone) Nanocapsules and Identification of Drug Degradation Products
    Camargo GA, Lyra AM, Barboza FM, et al. · Journal of nanoscience and nanotechnology · 2021 · 被引 3cited 3

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR PREPARATION OF TACROLIMUS
    PETKOVIC HRVOJE, KUSCER ENEJ, FUJS STEFAN, KOPITAR GREGOR, et al. · 公开号 WO2011004008WO2011004008 · 2011
  2. Process for preparation of tacrolimus
    PETKOVIC HRVOJE, KUSCER ENEJ, FUJS STEFAN, KOPITAR GREGOR, et al. · 公开号 AU2010270143AU2010270143 · 2012
  3. Process for Preparation of Tacrolimus
    — · 公开号 EP2272963EP2272963 · 2011
  4. TACROLIMUS PREPARATION FOR EXTERNAL APPLICATIONS
    MASUI HIRONORI, SATO SHIMPEI · 公开号 US2011212988US2011212988 · 2011
  5. TACROLIMUS PREPARATION FOR EXTERNAL APPLICATIONS
    MASUI HIRONORI, SATO SHIMPEI · 公开号 EP2345414EP2345414 · 2011

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

他克莫司 杂质谱研究要点Tacrolimus — impurity profiling notes

下面这些是拿到 他克莫司 的 40 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 40 impurity entries for Tacrolimus, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances